Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Bases de datos
Tipo del documento
Intervalo de año de publicación
2.
Artículo en Alemán | MEDLINE | ID: mdl-11324348

RESUMEN

UNLABELLED: Former studies demonstrated that small amounts of heparin might remain in the prepared retransfusion blood during intraoperative autotransfusion. This could lead to serious complications in patients suffering from heparin-induced-thrombocytopenia type II (HIT II). Lepirudin is an approved anticoagulant in HIT II-patients. We studied to what extent lepirudin is washed out during the preparation of retransfusion blood, when it is used as anticoagulant for the autotransfusion device cell saver 5. METHODS: We investigated four different concentrations of lepirudin solutions, 5 mg, 10 mg, 20 mg and 30 mg per litre normal saline. In order to imitate a clinical situation, each lepirudin solution was mixed with human blood in a 1:5-ratio and put into the reservoir of the cell saver. The device was started in the automatic mode using 1000 ml saline as washing solution. Several runs were carried out (five times using the 5 mg/l solution, ten times the 10 mg/l, eleven times the 20 mg/l and eleven times the 30 mg/l solution). The lepirudin concentration in the prepared retransfusion blood was measured. RESULTS: The median percentage reduction of the lepirudin content from the reservoir blood to the retransfusion blood was 100% for the 5 mg/l, 90.4% for the 10 mg/l, 94.3% for the 20 mg/l and 86.3% for the 30 mg/l solution. The differences of percentage reduction are not significant. But the different lepirudin concentrations in the anticoagulant solution have a significant influence on the lepirudin concentration in the retransfusion blood. The lepirudin concentration (median) in the retransfusion blood was 0.00 microgram/ml for the 5 mg/l, 0.16 microgram/ml for the 10 mg/l, 0.19 microgram/ml for the 20 mg/l and 0.66 microgram/l for the 30 mg/l lepirudin solution. CONCLUSION: Lepirudin as an anticoagulant for intraoperative autotransfusion is effectively eliminated using the cell saver 5 device in the automatic mode with 1000 ml saline as washing solution. A clinically relevant disturbance of coagulation is not to be expected, even if the highest concentration of lepirudin anticoagulant solution investigated in this study is used.


Asunto(s)
Anticoagulantes/sangre , Transfusión de Sangre Autóloga/métodos , Hirudinas/análogos & derivados , Hirudinas/sangre , Proteínas Recombinantes/sangre , Anticoagulantes/efectos adversos , Anticoagulantes/uso terapéutico , Transfusión de Sangre Autóloga/instrumentación , Terapia con Hirudina , Hirudinas/efectos adversos , Humanos , Periodo Intraoperatorio , Proteínas Recombinantes/efectos adversos , Proteínas Recombinantes/uso terapéutico
3.
Anaesthesist ; 50(1): 26-31, 2001 Jan.
Artículo en Alemán | MEDLINE | ID: mdl-11220255

RESUMEN

We investigated Danaparoid Sodium (Orgaran) as anticoagulant using three different concentrations (9, 4,5 or 3 U/ml anticoagulant solution) for the use in the autotransfusion device Cell Saver 5 (Haemonetics). Fresh units of whole blood packs were mixed in the reservoir in a proportion of 5:1 with the anticoagulant solution. Having started the Cell Saver 5 in the automatic mode, the amount of Danaparoid in the retransfusion blood was determined (chromogenic Antifactor-Xa test). The lowest concentration of the anticoagulant was applied in 4 patients with Heparin-induced Thrombocytopenia Type II undergoing total hip arthroplasty. There was a correlation between the concentration in the reservoir and in the retransfusion blood. None of the patients showed a disturbance of his coagulation system. One of them had slight clotting in the reservoir. We recommend the use of the lower concentrations tested: 4,5 U/ml or, particularly for patients with renal insufficiency or low body weight or expected high retransfusion volumes, 3 U/ml as anticoagulant concentrations. If the autotransfusion device is used according to the manufacturer's instructions there may be virtually no risk of clotting in the Cell Saver or of inhibition of the coagulation system in the patient.


Asunto(s)
Anticoagulantes/uso terapéutico , Transfusión de Sangre Autóloga/instrumentación , Sulfatos de Condroitina/uso terapéutico , Dermatán Sulfato/uso terapéutico , Heparitina Sulfato/uso terapéutico , Anticoagulantes/administración & dosificación , Coagulación Sanguínea/efectos de los fármacos , Volumen Sanguíneo , Sulfatos de Condroitina/administración & dosificación , Dermatán Sulfato/administración & dosificación , Combinación de Medicamentos , Factor Xa/análisis , Heparitina Sulfato/administración & dosificación , Humanos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA